PI
Mutations in p53 is a hallmark of tumor development leading to loss-of-function or gain-of-function. Consequently, cancer cells resist p53-dependent cell cycle checkpoints and intrinsic apoptosis. Intriguingly, the residual 50% of tumors can still progress with wildtype (wt)p53 indicating that these tumor cells have adapted alternative mechanisms suppressing wtp53 functions.
We have recently identified a non-canonical role of caspase-8 in the nucleus of MM that allows tumor cells with wildtype p53 (wtp53) activity to establish a de facto p53 protein loss, shifting cell fate from cell cycle arrest and apoptosis towards mitotic cell division at the G2/M checkpoint. In the nucleus, caspase-8
cleaves and inactivates the deubiquitinase USP28, preventing it from de-ubiquitinating and stabilizing wtp53. Integration of these different molecular
mechanisms may pave the way for the identification of new therapeutic targets or the reactivation of conventional approaches, like chemotherapy, to
provide improved and tailored treatment options.
Belval Riken room in BT2.
6, avenue du Swing L-4367
Belvaux, Luxembourg
LECTURE: 11:00am – 12:00pm
Webinar via Webex:
Event number: 2787 079 7302
Event password: RbhBmegU232
12:300pm – 13:30pm
Light lunch provided – Registration mandatory*
Supported by:
Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.